Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Biochemical Pharmacology|August 9, 1996
Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapyP H Houba, R G Leenders, E Boven, et al.
International Journal of Cancer|December 17, 1997
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcomaW J Jansen, G M Kolfschoten, C A Erkelens, et al.
European Journal of Cancer & Clinical Oncology|October 1, 1985
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude miceE Boven, M M Nauta, H M Schluper, et al.
Nuclear Medicine and Biology|February 18, 1998
[186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of the efficacy in experimental human ovarian cancerE Kievit, F B van Gog, H M Schlüper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicityF A van Acker, E Boven, K Kramer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1997
Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenograftsE Kievit, F B van Gog, H M Schlüper, et al.
British Journal of Cancer|April 15, 2004
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in ratsM Verschraagen, E Boven, E Torun, et al.
Gynecologic Oncology|February 22, 2002
Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatinG M Kolfschoten, T M Hulscher, S M Schrier, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 1998
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude miceA E Korst, E Boven, M L van der Sterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2011
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening methodR W F van Leeuwen, E L Swart, E Boven, et al.
Pageof 13